‘… they had interpreted “disability” as referring to a patently visible disability’: experience of a patient group with NICE-Reference-Cited by-同舟云学术

‘… they had interpreted “disability” as referring to a patently visible disability’: experience of a patient group with NICE

Published:2022-05-04 Issue:7 Volume:37 Page:1239-1245
ISSN:0968-7599
Container-title:Disability & Society
language:en
Short-container-title:Disability & Society

Author:

Barman-Aksözen Jasmin¹^ORCID,Granata Francesca¹^ORCID,Aksözen Mehmet Hakan¹^ORCID,Dechant Cornelia¹^ORCID,Falchetto Rocco¹^ORCID

Affiliation:

1. International Porphyria Patient Network, Zurich, Switzerland

Publisher

Informa UK Limited

Subject

General Social Sciences,General Health Professions,Health (social science)

Link

https://www.tandfonline.com/doi/pdf/10.1080/09687599.2022.2060804

Reference12 articles.

1. Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study

2. NICE and Fair? Health Technology Assessment Policy Under the UK’s National Institute for Health and Care Excellence, 1999–2018

3. Equality Act. 2010. “Definition of disability under the Equality Act 2010.” Accessed April 4, 2021. https://www.gov.uk/definition-of-disability-under-equality-act-2010

4. The Patient Perspective: A Matter of Minutes

5. Afamelanotide for Erythropoietic Protoporphyria

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study;International Journal of Environmental Research and Public Health;2023-03-28

2. Are payors ready for transparent prices yet?;The Lancet Regional Health - Europe;2022-08